MDR Annex XIV: What It Requires for Clinical Evaluation and PMCF
Clinical evaluation under the EU Medical Device Regulation is not simply the production of a Clinical Evaluation Report for certification.
MDR Annex XIV establishes a lifecycle process that starts with planning the clinical evaluation, continues through the identification, appraisal and analysis of clinical evidence, and extends after CE marking through Post-Market Clinical Follow-Up (PMCF).
For manufacturers, understanding Annex XIV is therefore fundamental to understanding what the MDR expects from the clinical evidence system as a whole.
MDCG 2020-5 at a Glance
Authority
Binding EU legislation
Applicable Since
26th May 2021
Current Status
In Force
Read Alongside
MDR Article 61, Annex II, Annex III and relevant MDCG clinical evaluation and PMCF guidance.
The Headline
Annex XIV is the principal procedural framework for clinical evaluation and PMCF under the MDR.
Part A sets out how manufacturers must plan, continuously conduct and document clinical evaluation. It requires a Clinical Evaluation Plan, systematic identification of relevant clinical data, appraisal of that data, generation of additional clinical data where necessary, analysis of the complete evidence base and documentation of the conclusions in a Clinical Evaluation Report.
Part B then extends that process into the post-market phase through PMCF.
The result is an interconnected clinical evidence system rather than a collection of isolated documents.
A Clinical Evaluation Plan establishes what needs to be demonstrated. The clinical evaluation determines whether the available evidence supports it. PMCF addresses continuing clinical questions after the device enters the market. New post-market evidence then feeds back into the clinical evaluation and risk management process.
That lifecycle relationship is one of the most important principles in Annex XIV.
What You Need to Know
A Clinical Evaluation Plan is Required
Annex XIV Part A requires manufacturers to establish and update a CEP before and throughout the clinical evaluation process.
The CEP must define what the clinical evaluation is intended to demonstrate.
This includes the intended purpose, target groups, clinical benefits, clinical safety methods, benefit-risk parameters and the manufacturer's clinical development strategy.
Clinical data must be identified systematically.
Manufacturers must identify available clinical data relevant to the device and its intended purpose, including identifying gaps in the clinical evidence through systematic scientific literature review.
Relevant clinical data must be critically appraised.
Finding clinical literature is not enough. The manufacturer must determine whether the evidence is suitable for demonstrating the safety and performance of the device.
Evidence gaps must be addressed.
Where the existing evidence does not resolve outstanding clinical questions, Annex XIV requires the generation of new or additional clinical data where necessary.
Clinical evaluation is a lifecycle process.
Article 61 requires the clinical evaluation and its documentation to be updated throughout the device lifecycle using clinical data generated through PMCF and PMS.
PMCF is part of a lifecycle system.
Annex XIV Part B defines PMCF as a continuous process that updates the clinical evaluation and requires manufacturers to address it within the PMS plan.
Where PMCF is not applicable, that position needs justification.
MDR Annex III requires the PMS plan to contain either a PMCF plan or a justification explaining why PMCF is not applicable.
Does This Apply to Your Device?
If you manufacture a medical device subject to the EU MDR, Annex XIV forms part of the regulatory framework governing your clinical evaluation.
It is particularly relevant if you are:
developing or updating a Clinical Evaluation Plan;
preparing or maintaining a Clinical Evaluation Report;
transitioning legacy clinical documentation developed under the MDD or AIMDD;
determining whether the available clinical evidence is sufficient;
planning PMCF activities;
preparing a PMCF Evaluation Report; or
reconciling clinical evaluation conclusions with PMS, risk management and post-market evidence.
For IVDs, the corresponding framework is different. Performance evaluation and Post-Market Performance Follow-Up are governed principally by Article 56 and Annex XIII of the IVDR rather than MDR Annex XIV.
Not sure whether your clinical evaluation system is keeping pace with MDR?
A 30-minute Clinical Evaluation Discovery Call gives you an opportunity to talk through your CEP, CER, PMCF strategy and current clinical evidence position with SciMed.
We can help you identify where the key evidence gaps, documentation disconnects or lifecycle challenges may sit - and what may need to be addressed.
What it Means Commercially
Annex XIV changes the commercial significance of clinical evaluation because the obligation does not end when the CER is completed or the device receives certification.
Clinical evidence has to be maintained across the device lifecycle.
That means the regulatory workload is not simply the cost of producing a CEP and CER for a submission. Manufacturers also need an appropriate system for maintaining the evidence base, monitoring the state of the art, integrating PMS and PMCF findings and updating clinical conclusions as the evidence develops.
Where that infrastructure is mature, the workload becomes relatively predictable.
Where it is not, problems often surface at precisely the least convenient point: during notified body review, certificate renewal, a significant device change or investigation of an emerging post-market issue.
The commercial question is therefore not simply, “Do we have a CER?”
It is, “Do we have a clinical evidence system that remains current and internally consistent?”
What it Means for Your Clinical Evaluation
The Clinical Evaluation Plan
Annex XIV Part A requires the manufacturer to establish and update a Clinical Evaluation Plan.
The regulation specifies at least eight elements for that plan:
the relevant General Safety and Performance Requirements that require support from clinical data;
the intended purpose;
target groups, indications and contraindications;
intended clinical benefits and relevant clinical outcome parameters;
methods for examining qualitative and quantitative aspects of clinical safety, including residual risks and side-effects;
parameters for determining the acceptability of the benefit-risk ratio against the state of the art;
how benefit-risk issues associated with particular components, such as medicinal substances or non-viable animal or human tissues, will be addressed; and
a clinical development plan, including relevant stages of clinical investigation and PMCF, milestones and potential acceptance criteria.
That final point is particularly important.
The CEP is not simply a contents page for the CER. It establishes the clinical evidence strategy: what needs to be demonstrated, how it will be demonstrated and how remaining evidence needs will be addressed across the lifecycle.
Identifying and appraising clinical data
Once the evaluation has been planned, Annex XIV requires the manufacturer to identify available clinical data relevant to the device and its intended purpose and to identify gaps in the evidence through systematic scientific literature review.
The relevant data then need to be appraised for their suitability in demonstrating device safety and performance.
This creates an important distinction between finding evidence and being able to rely on it.
A large body of literature does not necessarily amount to a strong clinical evidence base. Relevance to the actual device, intended purpose, claims, patient population and clinical questions still has to be established.
Generating additional clinical data
Annex XIV does not assume that literature review will always be sufficient.
Where outstanding clinical questions remain, the manufacturer must determine whether new or additional clinical data are needed and, where necessary, generate them through appropriately designed clinical investigations.
The required level of evidence is device-specific. Article 61 requires manufacturers to specify and justify the level of clinical evidence necessary in view of the characteristics and intended purpose of the device.
There is therefore no universal number of studies, patients or publications that automatically establishes sufficiency.
The Clinical Evaluation Report
The evidence identified, appraised and analysed through the clinical evaluation is ultimately documented in the Clinical Evaluation Report.
Article 61 requires the clinical evaluation, its results and the clinical evidence derived from it to be documented in a CER that forms part of the technical documentation, except in the case of custom-made devices.
The CER is therefore the conclusion of the evaluation process, not the process itself.
That distinction matters because a well-written report cannot compensate for weaknesses in the underlying evidence strategy.
What Annex XIV requires for PMCF
The PMCF Plan
Annex XIV Part B describes PMCF as a continuous process that updates the clinical evaluation.
Its purpose includes confirming safety and performance throughout the device's expected lifetime, identifying previously unknown side-effects, monitoring known side-effects and contraindications, identifying emerging risks, confirming continued acceptability of the benefit-risk ratio and identifying systematic misuse or off-label use.
Where PMCF is performed, it must follow a documented PMCF Plan.
That plan needs to define both general and specific PMCF methods, explain why those methods are appropriate, identify the objectives being addressed and provide an adequately justified timetable for the activities.
The method should therefore follow the unresolved clinical questions.
An annual literature search may form part of PMCF, but simply labelling an annual literature review “PMCF” does not demonstrate that the PMCF programme is appropriately designed to address the device's specific clinical uncertainties.
The PMCF Evaluation Report
The manufacturer must analyse the findings generated through PMCF and document them in a PMCF Evaluation Report.
Annex XIV states that this report forms part of the Clinical Evaluation Report and the technical documentation.
MDCG 2020-8 provides a structured template for documenting this evaluation and reinforces that the resulting conclusions should be considered when updating the clinical evaluation, risk management documentation, PMS plan and, where applicable, the Summary of Safety and Clinical Performance.
For Class III and implantable devices, Article 61 requires the PMCF Evaluation Report to be updated at least annually using the relevant clinical data.
Feeding PMCF back into clinical evaluation
The PMCF process is not complete when the PMCF Evaluation Report is written.
The findings have to be considered in the clinical evaluation and risk management process. If PMCF identifies a need for preventive or corrective measures, the manufacturer must implement them.
This feedback loop is central to the Annex XIV model:
Clinical evaluation → unresolved questions → PMCF → new clinical evidence → updated clinical evaluation.
That is why the CEP, CER, PMCF Plan and PMCF Evaluation Report should not evolve independently from one another.
Where Manufacturers Commonly Get this Wrong
Treating the CEP as an administrative document
A CEP can become a retrospective document written to accompany a CER that has already been completed.
That reverses its intended role.
The CEP should define the clinical questions, evidence requirements, benefit-risk parameters and clinical development strategy against which the evaluation is then conducted.
Confusing evidence collection with evidence sufficiency
Manufacturers can have extensive literature, PMS data and historical market experience while still having unresolved clinical evidence gaps.
Annex XIV requires the evidence to be appraised and analysed against the device's intended purpose, clinical benefits, safety, performance and benefit-risk conclusions.
Volume does not replace relevance or quality.
Allowing the CER and PMCF programme to drift apart
PMCF may be managed by one process while CER maintenance is managed by another.
The result can be a PMCF Evaluation Report that identifies uncertainty or new clinical information while the CER continues to repeat conclusions established several years earlier.
That is inconsistent with the lifecycle model Annex XIV establishes.
Using generic PMCF activities
A PMCF Plan that repeats the same activities for every device without connecting them to specific residual risks, uncertainties or clinical evidence needs may be difficult to defend.
Annex XIV requires the rationale for PMCF methods and the specific objectives being addressed to be documented.
Treating the CER as the clinical evaluation
The CER is the documented output of clinical evaluation.
Starting with the report structure rather than the clinical evidence questions can encourage teams to fill sections rather than determine whether the available evidence actually supports the device.
Priority Actions
If you are reviewing your Annex XIV position:
1. Confirm that an up-to-date Clinical Evaluation Plan exists and that it covers the minimum Annex XIV requirements.
2. Check that intended purpose, patient populations, indications, contraindications, claimed clinical benefits and clinical outcome parameters are consistent across the CEP, CER, risk documentation, labelling and other relevant technical documentation.
3. Confirm that the clinical evaluation identifies and appraises all relevant evidence rather than simply presenting selected favourable data.
4. Identify any unresolved clinical evidence gaps and determine how they are being addressed.
5. Review the PMCF strategy against those gaps, residual risks and remaining clinical uncertainties.
6. Confirm that PMCF findings are being analysed in a PMCF Evaluation Report and fed back into the CER and risk management process.
7. Check that the clinical evaluation is being maintained through the lifecycle rather than treated as a certification-only deliverable.
SciMed Perspective
The most useful way to read Annex XIV is not as a list of documents that need to exist.
It is as a description of the clinical evidence system that should connect them.
A strong CEP asks the right clinical questions. The clinical evaluation determines whether the available evidence answers them. Remaining uncertainty informs PMCF. PMCF generates additional clinical information. That information then changes, confirms or strengthens the conclusions in the clinical evaluation.
When those relationships work, CEPs, CERs and PMCF documents usually remain coherent.
When they do not, the symptoms appear as documentation problems, but the underlying issue is often evidence strategy rather than document writing.
That distinction is important when deciding how much remediation is actually required.
How SciMed Can Help
SciMed supports manufacturers across the Clinical Evaluation lifecycle, including Clinical Evaluation Plans, State-of-the-Art reviews, Clinical Evaluation Reports and ongoing clinical evaluation maintenance.
Our Post-Market Services also support the adjacent PMS and PMCF activities needed to maintain clinical evidence after market entry.
Where the existing position is unclear, SciMed can review the clinical evidence system as a whole: what the CEP requires, what the CER currently demonstrates, where evidence gaps remain and whether the PMS and PMCF strategy is capable of addressing them.
Primary Sources & Related Guidance
Primary Source
Regulation (EU) 2017/745, Annex XIV, Clinical Evaluation and Post-Market Clinical Follow-Up.
Related Legal Provisions
MDR Article 61, Clinical Evaluation.
MDR Annex II, Technical Documentation.
MDR Annex III, Technical Documentation on Post-Market Surveillance.
Related Guidance
MDCG 2020-7, Guidance on PMCF Plan Template.
MDCG 2020-8, Guidance on PMCF Evaluation Report Template.
MDCG 2020-5, Clinical Evaluation – Equivalence.
MDCG 2020-6, Guidance on Sufficient Clinical Evidence for Legacy Devices.
MEDDEV 2.7/1 Rev.4, Clinical Evaluation: A Guide for Manufacturers and Notified Bodies.
Need support with an equivalence or wider Clinical Evaluation issue?
Continue the Clinical Evaluation Source Series
This article is part of SciMed's Clinical Evaluation source series.
Related articles:
MDCG 2020-5: How to Demonstrate Equivalence Under EU MDR
MEDDEV 2.7/1 Rev.4 Under EU MDR: What Still Matters and What Has Changed
MDCG 2020-6: Clinical Evidence for Legacy Devices and the WET Route
